BioXcel Therapeutics (BTAI) Capital Expenditures (2018 - 2022)

BioXcel Therapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $19000.0 for Q2 2022.

• In Q2 2022, Capital Expenditures fell 95.33% year-over-year to $19000.0; the TTM figure through Sep 2023 stood at $19000.0 (down 87.42% YoY), while the FY2023 annual figure was $20000.0, down 85.61% from the prior year.
• Capital Expenditures was $19000.0 for Q2 2022 at BioXcel Therapeutics, down from $120000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $600000.0 in Q1 2019 to a low of -$5000.0 in Q3 2020.
• Historically, Capital Expenditures has averaged $124375.0 across 5 years, with a median of $39000.0 in 2019.
• Biggest YoY gain for Capital Expenditures was 13400.0% in 2020; the steepest drop was 111.63% in 2020.
• A 5-year view of Capital Expenditures shows it stood at $158000.0 in 2018, then slumped by 98.73% to $2000.0 in 2019, then surged by 13400.0% to $270000.0 in 2020, then slumped by 95.56% to $12000.0 in 2021, then jumped by 58.33% to $19000.0 in 2022.
• The last three Capital Expenditures figures came in at $19000.0 (Q2 2022), $120000.0 (Q1 2022), and $12000.0 (Q4 2021), per Business Quant data.